GridAI Technologies Corp.

GridAI Technologies Corp.

GRDX - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$35.37M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
GridAI Technologies Corp.GridAI Technologies Corp.-1.2--53%-0.1
$-0.74

Current Fair Value

115% downside

Overvalued by 115% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$35.37 Million
Enterprise Value$35.93 Million
Earnings per Share$-4.16
Beta1.7
Outstanding Shares6,419,222

Return

Return on Equity-53.47%ROE
Return on Assets-21.48%
Return on Invested Capital-97.62%

Valuation & Multiples

P/E Ratio-1.15P/E Ratio
PEG1.48PEG
Price to Sales-Price to Sales
Price to Book Ratio2.48Price to Book Ratio
Enterprise Value to Revenue224.11
Enterprise Value to EBIT-1.61
Enterprise Value to Net Income-5
Total Debt to Enterprise0.05
Debt to Equity0.13Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 21, 2026
EPS Estimate
$-11340.00
Consensus analyst estimate
Revenue Estimate
$85,876
Consensus analyst estimate

Next Earnings Call

Expected Date
November 16, 2026
EPS Estimate
$-11340.00
Consensus analyst estimate
Revenue Estimate
$85,876
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %0.00%▼ 9.94%
Total Invested$96▼ 100.00%
Investors Holding1▼ 18.00%

About First Wave BioPharma Inc

12 employees
CEO: James Sapirstein

AzurRx BioPharma, Inc. is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI assets. Th...